drugset / Trial / NCT02590523

Intracameral Antibiotic Safety Study

NCT02590523

Phase 3 Suspended 500 enrolled Panhandle Eye Group, LLP
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this study is to determine the safety (but not efficacy in preventing infection) of sterile-packaged and pre-loaded injectable solutions of both vancomycin and moxifloxacin at certain dosages and concentrations as prepared by a compounding pharmacy when used intracamerally at the time of cataract surgery.

Timeline

Start
2023-01
Primary completion
2024-01
Completion
2024-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 150 ug Other
Subject Vancomycin Other / unclassified 1 mg Other